Iradimed insider plans sale of 1,000 shares

A shareholder of Iradimed has filed a notice to sell 1,000 shares of common stock under Rule 144 through Raymond James on or around 02/13/2026, to be traded on NASDAQ.

Rhea-AI Filing Summary

A shareholder of Iradimed has filed a notice to sell 1,000 shares of common stock under Rule 144 through Raymond James on or around 02/13/2026, to be traded on NASDAQ. The filing lists an aggregate market value of 100,256.26 for the planned sale.

The 1,000 shares come from restricted stock units that vested on 12/07/2025 (95 shares) and 12/11/2025 (905 shares) as compensation for board service. The issuer had 12,722,377 shares outstanding when this notice was prepared.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Iradimed (IRMD) disclose?

The Form 144 discloses a planned sale of 1,000 Iradimed common shares under Rule 144. The seller intends to execute the trade through Raymond James on NASDAQ, with an aggregate market value reported as 100,256.26 at the time of the notice.

How many Iradimed (IRMD) shares are planned for sale and at what value?

The notice covers a planned sale of 1,000 Iradimed common shares with an aggregate market value of 100,256.26. This value reflects the market price used in the filing and helps indicate the approximate dollar size of the potential transaction.

When were the Iradimed (IRMD) shares in the Form 144 acquired?

The 1,000 shares come from RSU vestings on 12/07/2025 and 12/11/2025. The holder received 95 shares and 905 shares, respectively, from the issuer as compensation for board service, and is now seeking to sell those shares under Rule 144.

What is the approximate planned sale date in the Iradimed (IRMD) Form 144?

The filing lists an approximate sale date of 02/13/2026 for the 1,000 Iradimed common shares. This date reflects when the holder expects to begin selling through Raymond James on NASDAQ, subject to market conditions and applicable Rule 144 requirements.

How many Iradimed (IRMD) shares were outstanding when the Form 144 was filed?

The filing reports 12,722,377 Iradimed common shares outstanding. This figure provides context for the planned 1,000-share sale, showing the overall size of the company’s equity base relative to the contemplated Rule 144 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 03:20 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001253352
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IRADIMED CORP
SEC File Number	001-36534
Address of Issuer	12705 INGENUITY DRIVE ORLANDO FLORIDA 32826
Phone	407-677-8022
Name of Person for Whose Account the Securities are To Be Sold	MONTY K. ALLEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James 880 Carillon Parkway St. Petersburg FL 33716	1000	100256.26	12722377	02/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/07/2025	RSU Vesting	Issuer			95	12/07/2025	Board Service
Common	12/11/2025	RSU Vesting	Issuer			905	12/11/2025	Board Service

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Monty Allen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)